Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study

American Heart Journal

Volumn 157, Issue 2, 2009, Pages

  Marijon, Eloi ^a   Trinquart, Ludovic ^a,b   Otmani, Akli ^a   Waintraub, Xavier ^a   Kacet, Salem ^c   Clémenty, Jacques ^d   Chatellier, Gilles ^a,b   Le Heuzey, Jean Yves ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSERM   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; BRUGADA SYNDROME; CAUSE SPECIFIC SURVIVAL; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; FRANCE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; ISCHEMIC HEART DISEASE; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QRS COMPLEX; RISK ASSESSMENT; SUDDEN DEATH; VALVULAR HEART DISEASE;

EID: 58949090466     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.09.023     Document Type: Article

References (30)

1. Connolly S.J., Hallstrom A.P., Cappato R., et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs. implantable defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21 (2000) 2071-2078
2. Nanthakumar K., Epstein A.E., Kay G.N., et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 44 (2004) 2166-2172
3. Lee D.S., Green L.D., Liu P.P., et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 41 (2003) 1573-1582
4. Greenberg H., Case R.B., Moss A.J., et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 43 (2004) 1459-1465
5. Koller M.T., Schaer B., Wolbers M., et al. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study. Circulation 117 (2008) 1918-1926
6. Indications for automatic implantable ventricular defibrillators. French version. Bureau of Hearth Rhythm Group of the French Cardiology Society. Arch Mal Coeur Vaiss 93 (2000) 1227-1232
7. Vandenbroucke J.P. The making of STROBE. Epidemiology 18 (2007) 797-799
8. Fine J., and Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999) 496-509
9. Gray R. Subdistribution analysis of competing risks: the cmprsk library. Available at (2007). http://biowww.dfci.harvard.edu/~gray Last accessed August 23, 2007
10. Hinkle Jr. L.E., and Thaler H.T. Clinical classification of cardiac deaths. Circulation 65 (1982) 457-464
11. Heart Rhythm Society's Patient & Public Information Center. Available at (2008). http://www.hrspatients.org/patients/treatments/cardiac_defibrillators/de fault.asp Last accessed February 24, 2008
12. Ezekowitz J.A., Armstrong P.W., and McAlister F.A. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 138 (2003) 445-452
13. Anderson K.P. Sudden cardiac death unresponsive to implantable defibrillator therapy: an urgent target for clinicians, industry and government. J Interv Card Electrophysiol 14 (2005) 71-78
14. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
15. Cleland J.G., Daubert J.C., Erdmann E., et al. Longer-term effects of cardiac resynchronisation therapy on mortality in heart failure [the CArdiac Resynchronisation-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 27 (2006) 1928-1932
16. Gradaus R., Block M., Brachmann J., et al. Mortality, morbidity, and complications in 3344 patients with implantable cardioverter defibrillators: results from the German ICD Registry EURID. Pacing Clin Electrophysiol 26 (2003) 1511-1518
17. Tsai C.T., Huang S.K., Lin J.L., et al. Distinct clinical features in the recipients of the implantable cardioverter defibrillator in Taiwan: a multicenter registry study. Pacing Clin Electrophysiol 26 (2003) 2083-2090
18. Thibodeau J.B., Pillarisetti J., Khumri T.M., et al. Mortality rates and clinical predictors of reduced survival after cardioverter defibrillator implantation. Am J Cardiol 101 (2008) 861-864
19. Linde C., Gold M., Abraham W.T., et al. REVERSE Study Group. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure-the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Am Heart J 151 (2006) 288-294
20. Moss A.J., Brown M.W., Cannom D.S., et al. Multicenter automatic defibrillator implantation trial-cardiac resynchronisation therapy (MADIT-CRT): design and clinical protocol. Ann Noninvasive Electrocardiol 10 (2005) 34-43
21. Linde C. 12-Month results of the REVERSE study. Late-Breaking Clinical Trials II. American College of Cardiology 2008 Scientific Sessions; April 1, 2008. Chicago, IL (2008)
22. Bigger Jr. J.T., Whang W., Rottman J.N., et al. Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 99 (1999) 1416-1421
23. Southern D.A., Faris P.D., Brant R., et al. Kaplan-Meier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol 59 (2006) 1110-1114
24. Latouche A., Boisson V., Chevret S., et al. Misspecified regression model for the subdistribution hazard of a competing risk. Stat Med 26 (2007) 965-974
25. Pires L.A., Hull M.L., Nino C.L., et al. Sudden death in recipients of transvenous implantable cardioverter defibrillator systems: terminal events, predictors, and potential mechanisms. J Cardiovasc Electrophysiol 10 (1999) 1049-1056
26. Goldenberg I., Vyas A.K., Hall W.J., et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 51 (2008) 288-296
27. Mitchell L.B., Pineda E.A., Titus J.L., et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol 39 (2002) 1323-1328
28. Pratt C.M., Greenway P.S., Schoenfeld M.H., et al. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation 93 (1996) 519-524
29. Parkash R., Stevenson W.G., Epstein L.M., et al. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J 151 (2006) 397-403
30. Wilkoff B.L., Cook J.R., Epstein A.E., et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288 (2002) 3115-3123